InMed Pharmaceuticals (NASDAQ:INM) Issues Earnings Results

InMed Pharmaceuticals (NASDAQ:INM) announced its quarterly earnings results on Wednesday. The company reported ($3.64) earnings per share (EPS) for the quarter, Zacks reports. InMed Pharmaceuticals had a negative net margin of 137.41% and a negative return on equity of 65.74%.

InMed Pharmaceuticals Trading Up 3.9 %

INM stock opened at $3.20 on Thursday. The company has a current ratio of 5.07, a quick ratio of 4.22 and a debt-to-equity ratio of 0.08. InMed Pharmaceuticals has a 1 year low of $2.41 and a 1 year high of $15.70. The stock has a 50-day simple moving average of $4.35 and a 200-day simple moving average of $4.73.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.